Cerity Partners LLC Acquires New Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Cerity Partners LLC purchased a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,692 shares of the life sciences company’s stock, valued at approximately $291,000.

Several other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Integra LifeSciences by 1.0% in the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after acquiring an additional 72,294 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in Integra LifeSciences by 19.5% in the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after acquiring an additional 238,816 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Integra LifeSciences in the third quarter worth about $43,034,000. Assenagon Asset Management S.A. acquired a new stake in Integra LifeSciences in the third quarter worth about $25,443,000. Finally, Glenmede Trust Co. NA boosted its holdings in Integra LifeSciences by 45.6% in the third quarter. Glenmede Trust Co. NA now owns 306,032 shares of the life sciences company’s stock worth $11,687,000 after acquiring an additional 95,857 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on IART shares. JMP Securities decreased their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a report on Wednesday, April 3rd. Finally, Truist Financial decreased their target price on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Stock Down 0.2 %

Shares of IART stock opened at $28.34 on Friday. The stock has a 50 day moving average of $35.34 and a 200 day moving average of $38.76. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. The stock has a market cap of $2.23 billion, a P/E ratio of 34.14, a P/E/G ratio of 0.86 and a beta of 1.12. Integra LifeSciences Holdings Co. has a twelve month low of $27.18 and a twelve month high of $56.21.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.94 earnings per share. As a group, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.